{"id":"tp-52797","type":"article-newspaper","title":"Xenon Plans Q1 2027 Azetukalner Study With $1.2 Billion in Cash and Securities","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/52797","datePublished":"2026-11-10T04:12:38.000Z","dateModified":"2026-11-10T04:12:38.000Z","language":"en","abstract":"Xenon submitted a new drug application for focal seizures in Q3 2026; topline results from X-NOVA2 are expected in December.","section":"Business","references":[]}